

IMPORTANT SAFETY INFORMATION



for patients taking ZYNLONTA® (loncastuximab tesirine)

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See enclosed for details.

PATIENT ALERT CARD

INFORMATION FOR PATIENTS

This patient alert card contains important safety information that you need to be aware of during treatment with ZYNLONTA.

Read the Patient Information Leaflet (PIL) for more information.

Please always keep this card with you during treatment and show this card to any healthcare professional involved in your care.

- Treatment with ZYNLONTA can cause photosensitivity reactions (skin reactions after exposure to sunlight), through exposure to artificial sunlight, direct and indirect sunlight (such as through glass windows in vehicles and public transportation) including:
 - sunburn-like reactions such as skin peeling and irritation following exposure to light
 - itchy rash
 - blistering of skin
 - darker skin patches
 - irritation, swelling, pain
- **You must protect skin from exposure to sunlight by wearing sun-protective clothing and/or the use of sunscreen products during the entire treatment period**
- If you experience any of these skin reactions, you should immediately call your treating healthcare professional or seek emergency medical care and show this card right away

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the patient leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or the free Yellow Card app available from the Apple App Store or Google Play Store. Side effects should also be reported to Swedish Orphan Biovitrum Ltd via email at medical.info.uk@sobi.com or by calling +44 (0) 800 111 4754.

By reporting side effects you can help provide more information on the safety of this medicine.

CONTACT DETAILS

Patient name:

Prescribing hospital:

Prescribing Physician's name:

Prescribing Physician's telephone number:

INFORMATION FOR HEALTHCARE PROFESSIONALS

Please note that this patient is receiving treatment with ZYNLONTA (loncastuximab tesirine) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL).

- ZYNLONTA can cause photosensitivity reactions, including sunburn-like reactions such as skin peeling and irritation following exposure to light, itchy rash, blistering of skin, darker skin patches, irritation, swelling, pain
- ZYNLONTA should be withheld for severe (Grade 3) cutaneous reactions until resolution
- Dermatologic consultation should be considered
- Contact prescribing doctor (left) as soon as possible

REPORTING OF SUSPECTED ADVERSE REACTIONS:

▼ Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse reactions/events should also be reported to Swedish Orphan Biovitrum Ltd at medical.info.uk@sobi.com or by calling +44 (0) 800 111 4754.

For more information about ZYNLONTA, please refer to the full Summary of Product Characteristics or alternatively e-mail medical.info.uk@sobi.com or call +44 (0) 800 111 4754.

ZYNLONTA is a registered trademark of ADC Therapeutics SA.

© 2023 Swedish Orphan Biovitrum AB (publ) - All rights reserved.

Swedish Orphan Biovitrum Ltd,
Suite 2, Riverside 3, Granta Park,
Great Abington,
Cambridgeshire, CB21 6AD
www.sobi.com/uk/en

NP-28941 August 2023

